article thumbnail

The growing uses of medicinal cannabis

Pharmaceutical Technology

Demand for medicinal cannabis is increasing globally to treat a range of illnesses and conditions.

Medicine 340
article thumbnail

EMA issues guidance amidst European medicine shortage

Pharmaceutical Technology

The European Medicines Agency (EMA) has published recommendations to increase communication and planning efforts in a bid stop the current medicine shortages becoming even worse. The EMA set up a task force in 2016 in light of issues concerning medicine availability and supply chain.

Medicine 249
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ethnopharmacology: traditional medicine and modern drug discovery

Pharmaceutical Technology

Traditional medicine refers to the knowledge, skills and practices that indigenous and different cultures use to maintain health, encompassing forms such as herbal medicine, Traditional Chinese Medicine (TCM) and acupuncture. Studying the behaviour of animals can aid in drug discovery research too.

Medicine 262
article thumbnail

Roche bets on Ionis RNA medicines with neuroscience deal

Bio Pharma Dive

The Swiss drugmaker is restocking its pipeline by buying into preclinical Ionis medicines for Alzheimer’s and Huntington’s diseases.

Medicine 294
article thumbnail

The importance of high-quality raw materials in the development of Regenerative Medicine

Pharmaceutical Technology

Regulatory standards concerning raw material selection are particularly stringent when it comes to Regenerative Medicines.

Medicine 243
article thumbnail

European Commission bolsters defences against critical medicine shortages

Pharmaceutical Technology

The EC announced new initiatives to tackle critical medicine shortages in winter, introducing more flexibility to strengthen supplies.

Medicine 246
article thumbnail

Regenerative medicine: new focus on VEGF target?

Pharmaceutical Technology

Regenerative medicines in early-stage development (preclinical, discovery, or investigational new drug [IND]/ clinical trial application [CTA] filed status) have seen a change in drug targets compared to therapies in late-stage development (Phase II to pre-registration stage).

Medicine 246